Trials / Completed
CompletedNCT00114023
1-Year Follow up to the 1473-IMIQ Study
A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (planned)
- Sponsor
- Graceway Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod 5% cream |
Timeline
- Start date
- 2005-01-01
- First posted
- 2005-06-14
- Last updated
- 2007-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00114023. Inclusion in this directory is not an endorsement.